Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court To Consider Patent Use Codes, But At Best Can Give Generic Firms A Hunting License

This article was originally published in The Pink Sheet Daily

Executive Summary

The Supreme Court will address whether an ANDA sponsor can challenge a brand name company's alteration of a drug's patent use code to block generic competition.

You may also be interested in...



Is A Pharma Sales Rep A Salesman? Supreme Court To Make Final Call

Court to decide whether sales reps qualify for overtime pay in case involving former GlaxoSmithKline reps; it is the third pharma case this term.

Patent Use Codes: FDA Might Have Administrative Remedies, Solicitor General Says

In calling for the Supreme Court to take up a case involving the alteration of a patent use code to block generic competition, the Acting Solicitor General suggested steps FDA could take to address the problem.

Patent Code Changes: Dangerous Precedent Or Unique Circumstance? Supreme Court Seeks Government's Views

Generic companies contend that the Caraco v. Novo Nordisk case could enable brand firms to game the system and delay generic approvals; Novo says the case may never happen again.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel